CD11c(+) and IRF8(+) cell densities in rectal cancer biopsies predict outcomes of neoadjuvant chemoradiotherapy

Approximately 20% of locally advanced rectal cancer (LARC) patients treated preoperatively with chemoradiotherapy (CRT) achieve pathologically confirmed complete regression. However, there are no clinically implemented biomarkers measurable in biopsies that are predictive of tumor regression. Here, we conducted multiplexed immunophenotyping of rectal cancer diagnostic biopsies from 16 LARC patients treated preoperatively with CRT. We identified that patients with greater tumor regression had higher tumor infiltration of pan-T cells and IRF8(+)HLA-DR+ cells prior to CRT. High IRF8(+)HLA-DR+ cell density was further associated with prolonged disease-specific survival with 83% survival at 5 y compared to 28% in patients with low infiltration. Contrastingly, low CD11c(+) myeloid cell infiltration prior to CRT was a putative biomarker associated with longer 3- and 5-y disease-free survival. The results demonstrate the potential use of rectal cancer diagnostic biopsies to measure IRF8(+) HLA-DR+ cells as predictors of CRT-induced tumor regression and CD11c(+) myeloid cells as predictors of LARC patient survival.

Automated summary

By analyzing the immunophenotype of rectal cancer diagnostic biopsies from 16 LARC patients treated with CRT, it was found that patients with greater tumor regression had higher infiltration of pan-T cells and IRF8(+)HLA-DR+ cells prior to CRT. High density of IRF8(+)HLA-DR+ cells was associated with 83% survival at 5 years, while low infiltration of CD11c(+) myeloid cells was associated with longer 3- and 5-year disease-free survival. These findings suggest that measuring IRF8(+) HLA-DR+ cells and CD11c(+) myeloid cells in rectal cancer biopsies can predict CRT-induced tumor regression and survival in LARC patients.